Century Therapeutics Inc IPSC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.24
- Day Range
- $2.18–2.28
- 52-Week Range
- $0.44–3.04
- Bid/Ask
- $2.12 / $2.50
- Shares Outstanding
- 180.35M
- Market Cap
- $405.80M
- Volume/Avg
- 702,375 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 78
- Website
- https://www.centurytx.com
Valuation
|
Metric
|
IPSC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
IPSC
Financial Strength
|
Metric
|
IPSC
|
|---|---|
Quick Ratio | 9.94 |
Current Ratio | 10.25 |
Interest Coverage | — |
Quick Ratio
IPSC
Profitability
|
Metric
|
IPSC
|
|---|---|
Return on Assets (Normalized) | −34.10% |
Return on Equity (Normalized) | −45.30% |
Return on Invested Capital (Normalized) | −39.54% |
Return on Assets
IPSC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Fpffzkxn | Pjcqhz | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Twslxpmcl | Wsxqsqg | $64B | |||
| argenx SE ADR
ARGX
| Bbwfwcq | Ycsj | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mvzqrgcn | Htxrky | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Xhgtdfdnmx | Kfhmlrl | $24B | |||
| BioNTech SE ADR
BNTX
| Sgzfcnjch | Kcj | $23B | |||
| Incyte Corp
INCY
| Pldmqxcp | Tjdt | $22B | |||
| Moderna Inc
MRNA
| Styhtwvk | Vhsz | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Ksrkdjns | Tbykv | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Ghzktxhgk | Chmdz | $13B |
United States